VXRT - Complete data from Vaxart oral COVID-19 vaccine study in hamsters published

Full data is now available on a preclinical study that Vaxart (VXRT -0.8%) conducted in hamsters demonstrating the potential efficacy of its oral COVID-19 vaccine. Results have been published in The Journal of Infectious Diseases. In the study, hamsters were vaccinated orally or intranasally with the vaccine candidate and then exposed to high levels of the COVID-19 virus to promote vaccine breakthrough. Vaccinated hamsters cleared the virus in the nose and lungs quickly. Vaxart added that initial data from a phase 2 study in humans is expected in Q1 2022. Seeking Alpha contributor Chetan Woodun just wrote that because injectable vaccines seem to offer somewhat reduced protection against the delta variant, Vaxart's vaccine could be appealing for preventive purposes.

For further details see:

Complete data from Vaxart oral COVID-19 vaccine study in hamsters published